NEW YORK (360Dx) – Owlstone Medical today announced that it has completed a $50 million financing round to support the development and commercialization of a breath biopsy platform for early disease detection.
The funding includes a previously announced round valued at $15 million and brings the total raised by Cambridge, UK-based Owlstone to about $73 million since its founding in 2016.